3-(Trifluoromethyl)-5,6,7,8-tetrahydro-[1,2,4]triazolo[4,3-a]pyrazine hydrochloride is supplied as pharma-grade API under model designation TFMT-THP-HCl-PG for tablet, capsule, granule, injection, oral and injectable finished dosage forms. The empirical formula is C6H8ClF3N4; the relative molecular mass is 228.60 g/mol. The free base relative molecular mass is 192.14 g/mol. The compound is identified by CAS Registry Number 762240-92-6. The hydrochloride salt is a white to off-white crystalline powder. The saturated pyrazine ring differentiates the material from aromatic triazolopyrazine analogues: it lacks the planar π-system of the unsaturated parent and shows different pH-dependent solubility and hygroscopicity. The trifluoromethyl substituent modifies the electron density of the triazole ring, and the salt form is intended to increase aqueous processability relative to the free base. A 10 mg/mL aqueous solution of the hydrochloride should be checked for pH; if the measured pH exceeds 5.5, salt dissociation or free base contamination should be investigated by HPLC and chloride assay.

What Limits Direct Compression Utility of the Hydrochloride Form?

Direct compression is constrained by powder flow and compactibility of the incoming lot. A powder flow screen per Ph. Eur. 2.9.36 and USP <1174> should be applied before formulation. If bulk density is below 0.35 g/mL, Carr index exceeds 35, or Hausner ratio exceeds 1.35, direct compression without granulation is not recommended. When a high-speed rotary tablet press with 10 mm round concave tooling is used, the compaction force should be mapped between 12 kN and 20 kN. If the measured radial tensile strength exceeds 2.0 MPa, tablet porosity may fall sufficiently to slow dissolution in pH 1.2 media; the resulting tablets should be tested by USP <711> dissolution apparatus 2 at 50 rpm.

Lubricant overmixing is a processing conflict for this hydrochloride. Magnesium stearate at 1.0% w/w with blending times longer than 5 minutes should be evaluated on an instrumented tablet press rather than assumed from non-salt triazolopyrazine data. If compactability loss exceeds 20% relative to unlubricated blend, a more robust lubrication strategy is sodium stearyl fumarate at 0.5–1.5% w/w with blending limited to 3–5 minutes. For high-shear wet granulation, a 65 L bowl with impeller speed 300 rpm and chopper 1500 rpm for 3 minutes is a practical starting range. The hydrochloride has measurable aqueous solubility, so the binder solution can dissolve a fraction of the API during massing. Massing time should be less than 5 minutes, and fluid-bed drying inlet air temperature should be kept below 60 °C to reduce hydrate formation or polymorph conversion. Granule moisture should be confirmed by Karl Fischer titration; if water content exceeds 0.5% w/w, drying should continue or vacuum drying at 40–50 °C should be applied.

Particle engineering for capsule and granule operations shifts the control target from flow to bulk density and wetting. For hard gelatin capsules, a milled API fraction with D90 below 100 µm and D50 in the 30–50 µm range generally permits fill weight RSD below 2.0% on dosator-type capsule machines with pin agitation. For granule filling into stick packs, the formulated granules should be passed through a 1.0 mm sieve after dry sizing; the accepted granule fraction is typically 500–850 µm, with fines below 150 µm limited to 15% w/w to reduce dust formation and segregation. For injectable manufacture, the crystalline powder is dissolved and filtered through a 0.22 µm sterilizing-grade filter. Particulate matter in the final solution is controlled by light obscuration per USP <788>; subvisible particle limits apply for particles ≥10 µm and ≥25 µm. The solution filter compatibility should be confirmed with a small-scale filter adsorption study because the trifluoromethyl-containing API can show surface retention on some hydrophobic membrane materials; published data for this specific configuration are limited.

If the API Is Intended for Terminal Sterilization, Solution pH Must Be Mapped First

The triazolopyrazine ring can undergo pH-dependent degradation in aqueous solution. The hydrochloride salt dissolves to an acidic pH, and the pH profile should be mapped by potentiometric titration. For injectable products, citrate or acetate buffering at pH 4.0–5.5 is a conservative starting point, but actual excipient compatibility must be verified by forced degradation. A forced degradation study in stoppered glass vials at 80 °C for 7 days using pH 2.0, 4.5, 8.0, and 10.0 buffers is appropriate to identify pH-sensitive degradation pathways. Autoclaving at 121 °C for 15 minutes is acceptable only if the formulated solution shows assay loss below 2.0% and total degradation products below 0.5% after terminal sterilization. Otherwise, aseptic filtration through a 0.22 µm filter is the terminal processing route. When aseptic processing is used, the API powder must meet sterility and endotoxin limits before formulation. Dry heat sterilization is not recommended because the hydrochloride may undergo discoloration above 120 °C.

The hydrochloride differs from the free base in terminal filtration and vessel selection. The salt provides higher aqueous solubility at acidic pH, but chloride ion can contribute to corrosion of stainless steel if the solution is held at low pH and high concentration. Contact surfaces should be 316L stainless steel or glass-lined. If the formulated solution has chloride concentration above 0.1 M, storage time before filtration should be limited and the clean-in-place procedure should include passivation monitoring. The free base is less water-soluble and is generally not appropriate for direct injectable formulation without salt conversion.

Solid-State Identity and Reference Standard Qualification

The crystalline form should be identified by X-ray powder diffraction per USP <941> and thermal analysis per USP <891>. If the XRPD pattern contains a low-angle reflection shift after storage at 60% RH for 7 days, hydrate formation or deliquescence should be suspected. The hydrochloride should be stored in well-closed HDPE containers with LDPE liners at controlled room temperature and humidity not exceeding 40% RH. Pre-drying at 40 °C under vacuum may be required if the water content exceeds the route-specific limit. Reference standard qualification should be supported by quantitative NMR or mass balance, and the standard should be compared with the working in-house reference by HPLC area percent and residual solvent profile. Batch-to-batch variance in particle size after micronization should be tracked by USP <429> laser diffraction; incoming lots with D90 above 150 µm may require additional milling for oral solid dosage uniformity.

Residual solvent and elemental impurity control for this product follows ICH Q3C and ICH Q3D. Methanol is limited to 3000 ppm, dichloromethane to 600 ppm, and methyl tert-butyl ether to 5000 ppm; the actual panel is route-specific and must be confirmed from the supplier manufacturing process. Elemental impurities are evaluated by ICP-MS with oral and injectable permissible daily exposure limits for Class 1 and Class 2A elements. The final container closure system for oral powder should be HDPE with LDPE liner; for injectable use, glass vials with bromobutyl rubber stoppers and nitrogen overlay are appropriate. Bacterial endotoxin is controlled below 0.25 EU/mg for injectable, and total aerobic microbial count is held below 10² CFU/g. The API is not intended for dry-heat sterilization; terminal sterilization of a formulated solution must be supported by degradation data generated in the target buffer and container closure system.